Journal profile · Cardiac & Cardiovascular Systems
American Journal of Cardiovascular Drugs
ISSN 1175-3277 · eISSN 1179-187X · Springer International Publishing · NEW ZEALAND · Bimonthly · Founded 2001
American Journal of Cardiovascular Drugs: CAS Zone 3 · Medicine (2025 upgraded edition); impact factor 3.22; hybrid open access; APC about USD 4,790; median 134 days to acceptance (44 articles, last 24 months); community-reported acceptance: fairly easy; 67 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
American Journal of Cardiovascular Drugs is published by Springer International Publishing and is in Zone 3 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Atrial Fibrillation Management and Outcomes, Lipoproteins and Cardiovascular Health and Antiplatelet Therapy and Cardiovascular Diseases, together about 28.8% of its articles. Its main subfields are Cardiology and Cardiovascular Medicine. (generated from OpenAlex topic counts and CAS ranking data)
The American Journal of Cardiovascular Drugs promotes rational therapy and effective patient management within the discipline of cardiology by providing a regular program of independent review articles covering all aspects of the management of cardiovascular disorders, particularly the place in therapy of newer and established agents and procedures. The journal includes: Short overviews of contentious or emerging issues (Current Opinions and Leading Articles, respectively). Comprehensive narrative reviews on therapeutic approaches to managing cardiovascular disease. Systematic reviews that collate empirical evidence to answer a specific research question, using explicit, systematic methods as outlined by the PRISMA statement. Therapy in practice reviews covering optimum management of specific conditions. Adis Drug Reviews of the properties and place in therapy of both newer and established drugs in cardiovascular medicine. Original research articles reporting the results of well-designed clinical studies, such as clinical pharmacodynamic and pharmacokinetic studies, clinical trials, meta-analyses, outcomes research, and pharmacoeconomic studies.
From the journal's Aims & Scope
Research area (LetPub): Cardiac & Cardiovascular Systems
Editorial board by country: none in mainland China; most named United States 17, India 3, France 3, Italy 3, New Zealand 2 (33 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Atrial Fibrillation Management and OutcomesMedicine10.4%
- Lipoproteins and Cardiovascular HealthMedicine9.4%
- Antiplatelet Therapy and Cardiovascular DiseasesMedicine9.1%
- Heart Failure Treatment and ManagementMedicine8.1%
- Blood Pressure and Hypertension StudiesMedicine7.8%
- Acute Myocardial Infarction ResearchMedicine5.7%
- Venous Thromboembolism Diagnosis and ManagementMedicine5.2%
- Diabetes Treatment and ManagementMedicine4.9%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Pharmacology & Pharmacy | Zone 3 |
| Minor | Cardiac & Cardiovascular Systems | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Cardiac & Cardiovascular Systems | Zone 3 |
| Minor | Pharmacology & Pharmacy | Zone 2 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Cardiac & Cardiovascular Systems | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 4 |
Top journal: noReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
MEDLINEEmbaseCASCurrent ContentsPublisher website
Other: Google Scholar, EBSCO, ProQuest, Dimensions, CNKI, Baidu, Naver, OCLC, Portico, CLOCKSS, Semantic Scholar
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 3.22LetPub ·
- Impact factor (publisher) 2025
- 3.2Publisher website ·
- 5-year impact factor (publisher) 2025
- 2.8Publisher website ·
- CiteScore 2026-06
- 6LetPub ·
- SJR 2026-06
- 0.95LetPub ·
- SNIP 2026-06
- 0.99LetPub ·
- h-index
- 46LetPub ·
- h-index
- 74OpenAlex ·
- i10-index
- 757OpenAlex ·
- 2-year mean citedness
- 3.98OpenAlex ·
- Self-citation rate
- 0%LetPub ·
- Share of gold OA articles
- 28.49%LetPub ·
Volume
- Articles per year
- 52LetPub ·
- Articles per year (publisher)
- 2,025Publisher website ·
- Downloads per year (publisher) 2025
- 319,100Publisher website ·
Articles by year OpenAlex count · 1,416 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 44 | 11 | 9 |
| 2025 | 67 | 18 | 238 |
| 2024 | 91 | 27 | 556 |
| 2023 | 62 | 23 | 626 |
| 2022 | 42 | 19 | 503 |
| 2021 | 59 | 28 | 788 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
134 daysMedian, submission to acceptance · P25–P75 89 days – 206 days
- Acceptance to online
- median 24 days (90 articles)
- Submission to online
- median 156 days
- Sample
- 44 articles with submission and acceptance dates (145 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- over 12 weeksLetPub ·
- Average acceptance (community reports)
- Fairly easyLetPub ·
- Submission to first decision
- 7 daysPublisher website ·
- Peer review
- Double anonymous peer reviewPublisher website
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| OpenAlex | USD 4,790 / EUR 3,790 / GBP 2,990 | — | — |
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare5 items from the author guidelines
- Abstract
- 150–250 words
- Manuscript length
- ≤ 10,000 words
- Reference style
- Numbered, in order of citation
- Suggested reviewers
- Optional
- Cover letter
- Required
Article types accepted11
- editorialInternal Review by Editorial Staff: The journal editor will perform an initial appraisal of each manuscript. When submitting your paper, please include a coveri…Length not stated
- meta-analysisPlease note: Please note: There is no limit on the number of tables, figures or references that can accompany an article. Information that is relevant but not c…Length not stated
- opinionPlease note: Please note: There is no limit on the number of tables, figures or references that can accompany an article. Information that is relevant but not c…Length not stated
- original researchPlease note: Please note: There is no limit on the number of tables, figures or references that can accompany an article. Information that is relevant but not c…Length not stated
- original research articlePlease note: Please note: There is no limit on the number of tables, figures or references that can accompany an article. Information that is relevant but not c…Length not stated
- perspectivePlease note: Please note: There is no limit on the number of tables, figures or references that can accompany an article. Information that is relevant but not c…Length not stated
- protocolPlease note: Please note: There is no limit on the number of tables, figures or references that can accompany an article. Information that is relevant but not c…Length not stated
- research articlePlease note: Please note: There is no limit on the number of tables, figures or references that can accompany an article. Information that is relevant but not c…Length not stated
- reviewPlease note: Please note: There is no limit on the number of tables, figures or references that can accompany an article. Information that is relevant but not c…Length not stated
- review articlePlease note: Please note: There is no limit on the number of tables, figures or references that can accompany an article. Information that is relevant but not c…Length not stated
- systematic reviewPlease note: Please note: There is no limit on the number of tables, figures or references that can accompany an article. Information that is relevant but not c…Length not stated
Policy excerpts from the journal's websiteAI use, Authorship, Conflicts of interest, Data availability, License & copyright, Open access, Trial registration / reporting guidelines
- AI use Generative AI Images
Please check Springer’s policy on generative AI images and make sure your work adheres to the principles described therein. Back to top
Source ↗Publisher website ·- Authorship Authorship Principles
These guidelines describe authorship principles and good authorship practices to which prospective authors should adhere to. Authorship clarified The Journal and Publisher assume all authors agreed with the content and that all gave explicit consent to submit and that they obtained consent from the responsible authorities at the institute/organization where the work has been carried out, before th…
Source ↗Publisher website ·- Conflicts of interest Disclosures and declarations
All authors are requested to include information regarding sources of funding, financial or non-financial interests, study-specific approval by the appropriate ethics committee for research involving humans and/or animals, informed consent if the research involved human participants, and a statement on welfare of animals if the research involved animals (as appropriate). The decision whether such …
Source ↗Publisher website ·- Data availability Data availability statements
All original research must include a data availability statement. This statement should explain how to access data supporting the results and analysis in the article, including links/citations to publicly archived datasets analysed or generated during the study. Please see our full policy here. If it is not possible to share research data publicly, for instance when individual privacy could be com…
Source ↗Publisher website ·- License & copyright Copyright and license term – CC BY-NC
Open Choice articles do not require transfer of copyright as the copyright remains with the author. In opting for open access, the author(s) agree to publish the article under the Creative Commons Attribution-NonCommercial 4.0 International License Find more about the license agreement Back to top
Source ↗Publisher website ·- Open access Open access publishing
To find out more about publishing your work Open Access in American Journal of Cardiovascular Drugs, including information on fees, funding and licences, visit our Open access publishing page. Back to top
Source ↗Publisher website ·- Trial registration / reporting guidelines Clinical Trial Registration
The World Health Organization (WHO) definition of a clinical trial is "any research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes". The WHO defines health interventions as “A health intervention is an act performed for, with or on behalf of a person or population whose purpose is to ass…
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Springer International Publishing
- Country or region
- NEW ZEALAND
- Language
- English
- Frequency
- Bimonthly
- Founded
- 2001
- ISSN
- 1175-3277
- Electronic ISSN
- 1179-187X
- Latest issue on the website
- Volume 26, Issue 5 (September 2026)
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗LetPub
- Author guidelines ↗LetPub
- Special issues ↗Publisher website
FAQ
Frequently asked questions about American Journal of Cardiovascular Drugs
What CAS zone is American Journal of Cardiovascular Drugs in?
In the 2025 upgraded edition of the CAS Journal Ranking, American Journal of Cardiovascular Drugs is in Zone 3 of Medicine, and in Zone 3 of the minor category Pharmacology & Pharmacy / Cardiac & Cardiovascular Systems. In the 2026 Xinrui edition it is in Zone 2 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of American Journal of Cardiovascular Drugs?
The latest impact factor listed by LetPub is 3.22; CiteScore 6, h-index 74.
How long does peer review take at American Journal of Cardiovascular Drugs?
Based on the dates recorded on 44 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 134 days (interquartile range 89–206 days); authors report an average review time of over 12 weeks; the community-reported acceptance is “Fairly easy”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of American Journal of Cardiovascular Drugs?
According to the journal's author guidelines: Abstract: 150–250 words; Manuscript length: ≤ 10,000 words; Reference style: Numbered, in order of citation; Suggested reviewers: Optional; Cover letter: Required. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of American Journal of Cardiovascular Drugs based?
Of the 33 board members whose country the journal's board page names, none are in mainland China; the countries named most often are United States (17), India (3) and France (3). Counted from the institutions listed on the board page; for reference only.
Which databases index American Journal of Cardiovascular Drugs?
According to LetPub and DOAJ records, American Journal of Cardiovascular Drugs is indexed in SCIE and Scopus. The journal's website also lists MEDLINE, Embase, CAS and Current Contents; that list has not been checked against each database.
Is American Journal of Cardiovascular Drugs open access, and what is the APC?
American Journal of Cardiovascular Drugs is a hybrid journal. For open-access publication: APC about USD 4,790.
Sources and updates
The facts on this page come from LetPub, OpenAlex, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .